These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25352499)

  • 1. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer.
    Wang B; Yu W; Guo J; Jiang X; Lu W; Liu M; Pang X
    J Pharmacol Exp Ther; 2015 Jan; 352(1):129-38. PubMed ID: 25352499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.
    Zhengfu H; Hu Z; Huiwen M; Zhijun L; Jiaojie Z; Xiaoyi Y; Xiujun C
    Biochem Biophys Res Commun; 2015 Aug; 464(2):422-7. PubMed ID: 26102035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma.
    Sun CC; Zhang YS; Xue X; Cheng YN; Liu HP; Zhao CR; Lou HX; Qu XJ
    Eur J Pharmacol; 2011 Sep; 667(1-3):136-43. PubMed ID: 21704029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.
    Bhat TA; Nambiar D; Pal A; Agarwal R; Singh RP
    Carcinogenesis; 2012 Feb; 33(2):385-93. PubMed ID: 22139440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhizoma Paridis ethanol extract selectively inhibits the proliferation of HUVECs comparing to Lovo cells and shows anti-angiogenesis effects in a mouse model.
    Qian X; Zhu L; Hu J; Li M; Xie L; Wang L; Yu L; Liu B
    J Ethnopharmacol; 2012 Aug; 143(1):256-61. PubMed ID: 22750432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
    Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
    J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
    Hu J; Cheng Y; Li Y; Jin Z; Pan Y; Liu G; Fu S; Zhang Y; Feng K; Feng Y
    Eur J Cancer; 2014 Sep; 50(13):2336-50. PubMed ID: 25001183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative.
    Zhang Y; Zhang H; Chen J; Zhao H; Zeng X; Zhang H; Qing C
    Invest New Drugs; 2012 Feb; 30(1):8-16. PubMed ID: 20711631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.
    Aftab BT; Dobromilskaya I; Liu JO; Rudin CM
    Cancer Res; 2011 Nov; 71(21):6764-72. PubMed ID: 21896639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.